Home

Ardelyx, Inc. - Common Stock (ARDX)

5.4700
+0.00 (0.00%)
NASDAQ · Last Trade: May 2nd, 8:03 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close5.470
Open-
Bid4.400
Ask4.490
Day's RangeN/A - N/A
52 Week Range4.020 - 9.330
Volume152,205
Market Cap564.06M
PE Ratio (TTM)-34.19
EPS (TTM)-0.2
Dividend & YieldN/A (N/A)
1 Month Average Volume5,424,050

Chart

About Ardelyx, Inc. - Common Stock (ARDX)

Ardelyx Inc is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and kidney-related diseases. The company is committed to creating targeted treatments that address significant unmet medical needs, leveraging its proprietary platform to discover and advance novel compounds. Ardelyx’s research and development efforts aim to improve the quality of life for patients suffering from conditions such as chronic kidney disease and irritable bowel syndrome, with a focus on delivering effective and safe therapeutic options. Read More

News & Press Releases

Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · May 2, 2025
Get insights into the top gainers and losers of Thursday's after-hours session.chartmill.com
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · May 1, 2025
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · May 1, 2025
Earnings Scheduled For May 1, 2025benzinga.com
Via Benzinga · May 1, 2025
Breaking Down Ardelyx: 4 Analysts Share Their Viewsbenzinga.com
Via Benzinga · February 21, 2025
Earnings Scheduled For February 20, 2025benzinga.com
Via Benzinga · February 20, 2025
What Analysts Are Saying About Ardelyx Stockbenzinga.com
Via Benzinga · January 27, 2025
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stockbenzinga.com
Via Benzinga · January 2, 2025
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year
By Ardelyx, Inc. · Via GlobeNewswire · May 1, 2025
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company’s board of directors.
By Ardelyx, Inc. · Via GlobeNewswire · April 29, 2025
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company’s first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the upcoming Digestive Disease Week Conference (DDW), to be held May 3-6, 2025, in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
By Ardelyx, Inc. · Via GlobeNewswire · April 24, 2025
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Conference call scheduled for 4:30 p.m. Eastern Time
By Ardelyx, Inc. · Via GlobeNewswire · April 17, 2025
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.
By Ardelyx, Inc. · Via GlobeNewswire · April 10, 2025
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was accepted as a poster presentation at the National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 10-13, 2025, in Boston.
By Ardelyx, Inc. · Via GlobeNewswire · March 31, 2025
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy
By Ardelyx, Inc. · Via GlobeNewswire · March 13, 2025
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval
By Ardelyx, Inc. · Via GlobeNewswire · February 26, 2025
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:
By Ardelyx, Inc. · Via GlobeNewswire · February 25, 2025
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimismstocktwits.com
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.
Via Stocktwits · February 20, 2025
Ardelyx Tops Estimates as Sales Surgefool.com
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
Via The Motley Fool · February 20, 2025
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?benzinga.com
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session.
Via Benzinga · February 20, 2025
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales
By Ardelyx, Inc. · Via GlobeNewswire · February 20, 2025
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
By Ardelyx, Inc. · Via GlobeNewswire · February 19, 2025
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Conference call scheduled for 8:00 a.m. Eastern Time
By Ardelyx, Inc. · Via GlobeNewswire · January 30, 2025
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited)
By Ardelyx, Inc. · Via GlobeNewswire · January 13, 2025
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.
By Ardelyx, Inc. · Via GlobeNewswire · January 6, 2025